top of page
Asset 1@3x.png

Pioneering the development of novel immunotherapies for patients with blood cancers and B-cell disorders.

News & Events

HaemaLogiX Ltd, a clinical stage biotech, is pleased to announce the appointment of Laurence Turka, M.D. to its board as a non-executive director.

HaemaLogiX announces appointment of Laurence Turka, M.D. as a Non-Executive Director

31 January 2024
HaemaLogiX appoints haematologist Angela Dispenzieri, M.D. to its Scientific Advisory Board

HaemaLogiX appoints haematologist Angela Dispenzieri, M.D. to its Scientific Advisory Board

30 January 2024
HaemaLogiX’s South Korea patent “Kappa Myeloma Antigen Chimeric Receptors and Uses Thereof” was granted in South Korea on 5 January 2024.

HaemaLogiX announces issuance of South Korean patent for KMA.CAR-T

15 January 2024

Our Team

The HaemaLogiX management team has deep expertise in immunotherapy development and the unique antigens that our treatments target. Our Scientific Advisory Board comprises internationally recognised experts in monoclonal antibodies and haematology. 

Asset3@3x.png
Asset 4@3x.png

Our Pipeline

We’re developing a suite of diverse immunotherapies including monoclonal antibodies, CAR-T cells and bispecific antibodies, with a key focus on treating multiple myeloma and early investigation of AL Amyloidosis. 

Our Innovation

Our immunotherapies are designed to target and attack two unique antigens expressed on malignant cells – these antigens are not found on normal cells or tissues - making our treatments unlike others on the market. 

car-t ell.png
bottom of page